Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Denosumab [USAN:INN:BAN]
RN: 615258-40-7


  • A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS.
  • A receptor activator of nuclear factor-K B ligand (RANKL) inhibitor.

    NCI: A humanized monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. (NCI Thesaurus)

Molecular Formulas

  • C6404-H9912-N1724-O2004-S50
  • Unspecified

Classification Codes

  • Bone Density Conservation Agents
  • Prevention and Treatment of All Forms of Osteoporosis or Bone Lose
  • Prevention and Treatment of All Forms of Osteoporosis or Bone Loss

Names and Synonyms

Name of Substance

  • Denosumab
  • Denosumab [USAN:INN:BAN]

MeSH Heading

  • Denosumab


  • AMG 162
  • Denosumab
  • Denosumab (genetical recombination)
  • Prolia
  • Xgeva

Systematic Name

  • Immunoglobulin G2, anti-(human osteoclast differentiation factor) (human monoclonal AMG162 heavy chain), disulfide with human monoclonal AMG162 light chain, dimer

Registry Numbers

CAS Registry Number

  • 615258-40-7


  • 4EQZ6YO2HI

Other Registry Number

  • 847987-83-1

System Generated Number

  • 0615258407